Shanzha Uterine Perfusion Solution Veterinary Grade API is manufactured from the dried ripe fruit of Crataegus pinnatifida Bunge (Rosaceae), processed by aqueous-ethanolic extraction followed by vacuum concentration and standardized against quantitative HPLC-DAD marker profiles. The liquid concentrate functions as the active substance for downstream veterinary pharmaceutical manufacturers producing finished dosage forms intended for intrauterine administration across food-producing and companion animal species. The extraction manufacturing stream operates under veterinary Good Manufacturing Practice conditions aligned with VICH GL1 (validation of analytical procedures: definition and terminology), VICH GL2 (validation of analytical procedures: methodology), and VICH GL18 (impurities: residual solvents in new veterinary medicinal products). Residual ethanol in the as-supplied API is controlled to NMT 0.5% (w/v) via capillary gas chromatography with headspace sampling and flame ionization detection adapted from USP <467>. Heavy metal burden is verified per USP <233> with acceptance limits of NMT 2 ppm lead, NMT 0.5 ppm cadmium, NMT 1 ppm arsenic, and NMT 0.1 ppm mercury, consistent with the corresponding heavy metal thresholds in the Chinese Veterinary Pharmacopoeia 2020 edition. Microbiological quality of the liquid API is maintained at NMT 10² CFU/mL total aerobic microbial count and NMT 10¹ CFU/mL total combined yeast and mold count, while Escherichia coli, Salmonella species, and Staphylococcus aureus are confirmed absent in 1.0 mL aliquots per USP <62> screening methods. In the as-supplied concentrated liquid form, the API exhibits a total solids content of 20-28% (w/v), a pH of 4.0-5.5, and a relative density of 1.08-1.14 g/cm³ at 25°C; these parameters are confirmed at batch release by refractometric dry-substance determination, potentiometric pH measurement, and pycnometric density assay. The phytochemical profile is standardized to triterpenic acid and flavone glycoside marker classes, with quantitative batch-to-batch variance in total marker content held to ±1.5% absolute by blending of extraction lots. The pharmacodynamic rationale for intrauterine perfusion derives from the documented uterine smooth muscle contractile enhancement associated with triterpenic acid fractions in C. pinnatifida, alongside reported cyclooxygenase-2 inhibitory activity attributed to chlorogenic acid derivatives; these mechanisms support use in involution delay, lochia retention, and post-breeding uterine fluid accumulation. Published mechanistic data for this specific extract configuration in target species remains limited, and downstream manufacturers are advised to conduct species-specific dose-confirmation studies prior to regulatory submission.

In dairy operations where postpartum uterine disease prevalence exceeds 20% during the first 30 days in milk among high-yielding Holstein herds, intrauterine perfusion with Shanzha-derived API solutions is administered as an adjunct to systemic antimicrobial therapy only after ultrasonographic confirmation of uterine fluid accumulation and cytological evidence of inflammation defined by polymorphonuclear neutrophil proportions exceeding 18% on endometrial cytology smears. The industry compliance framework for this application is governed by VICH GL49 (studies to evaluate the safety of residues of veterinary drugs in human food: general approach to establish an MRL), EU Regulation 2019/6 on veterinary medicinal products, and FDA CVM guidance for reproductive tract therapeutics in lactating dairy animals. The formulation addition ratio for the working irrigation solution requires dilution of the concentrated API with sterile 0.9% sodium chloride injection at 1:10 to 1:20 (v/v), yielding a final total solids concentration of 1.0-2.8% (w/v) and a working pH of 5.8-6.8 adjusted with 0.1 M sodium hydroxide where required. Downstream pharmaceutical manufacturers aseptically transfer the diluted solution into sterile, non-pyrogenic containers via peristaltic pump filling lines operating at 5-10 mL/min flow rates with in-line 0.22 µm PVDF filtration immediately prior to filling; the filling is conducted in a Grade C environment with Grade A local protection per EU GMP Annex 1. The terminal product configurations for the dairy cattle segment include 500 mL high-density polyethylene bottles with tamper-evident caps, 100 mL PVC-free flexible irrigation bags suitable for gravity-fed administration, and 20 mL single-dose polypropylene devices pre-filled under aseptic conditions for individual animal treatment. On-farm administration is performed postpartum day 21-28 after Metricheck vaginal discharge scoring (scale 0-3; treatment indicated at scores 2-3) using a sterile, single-use, 60-80 cm bovine uterine catheter advanced through the cervical canal with rectal palpation guidance; infusion volumes of 50-100 mL are delivered by gravity or low-pressure syringe, with operators instructed to avoid infusion pressures exceeding 100 mmHg to prevent reflux of contaminated fluid into the oviducts. Observation of batch-to-batch variance on production lines confirms that concentrated API with total solids exceeding 28% exhibits increased viscosity that reduces peristaltic pump filling accuracy by 3-5% relative to target fill weights, necessitating dilution to specification before transfer to the filling manifold. Storage stability data for the concentrated API supports 24-month shelf life at 15-25°C in sealed, light-protected containers, while diluted working solutions are assigned a 24-hour shelf life at 2-8°C due to the absence of preservative systems.

What Limits Intrauterine Retention After Farrowing in High-Parity Sows?

Post-farrowing intrauterine perfusion in high-parity sow units addresses the metritis-mastitis-agalactia (MMA) syndrome complex, where uterine bacterial colonization by Escherichia coli, Trueperella pyogenes, and anaerobic Fusobacterium necrophorum establishes within 12-48 hours of parturition. The limiting factor governing therapeutic efficacy in this segment is intrauterine retention time: fluids infused immediately post-farrowing are expelled within 30-60 minutes by ongoing myometrial contractions unless the working solution viscosity is increased through dilution ratios at the lower end of the specified range. Formulation addition ratios for sow uterine irrigation specify API dilution with sterile 0.9% saline at 1:5 to 1:15 (v/v), producing final total solids concentrations of 1.3-5.6% (w/v); the higher-concentration end of this range (1:5 dilution) is reserved for herds with documented severe post-partum discharge, while 1:10 to 1:15 dilutions are applied as prophylactic protocol following farrowing difficultly classified by a farrowing assistance score of 2 or greater. The compliance standards governing this application derive from EC No 470/2009 for maximum residue limits in porcine edible tissues, the Chinese Ministry of Agriculture and Rural Affairs Announcement No. 2428 governing veterinary drug use in food animals, and GB/T 14699.1-2017 for sampling of veterinary drug raw materials. The downstream production process for sow-specific finished products involves aseptic dilution of the concentrated API in stainless steel jacketed vessels equipped with bottom-mount magnetic stirrers operating at 250-350 rpm, followed by 0.45 µm pre-filtration and terminal 0.22 µm sterilizing filtration into sterile holding tanks. Filling into 20 mL single-use high-pressure LDPE tubes, 50 mL amber glass vials with rubber stoppers, and 100 mL low-density polyethylene irrigation bottles proceeds on rotary piston pump fillers calibrated to deliver volumetric accuracy of ±1.5% of target volume. On-farm administration is conducted within 12-24 hours post-farrowing via a sterile spirally tipped porcine artificial insemination catheter (50 cm length, 8 mm outer diameter) inserted through the relaxed post-partum cervix; infusion volumes of 20-40 mL are delivered slowly over 2-3 minutes with the sow in ventral recumbency. Field observations from farrowing units using the 40 mL infusion volume report leakage from the vulva during the first 15 minutes post-infusion in 10-15% of treated sows when administration is performed earlier than 12 hours post-farrowing, supporting the specified minimum intervention window. Terminal product stability for 20 mL LDPE tubes is assigned at 18 months at 15-25°C, with photostability data confirming no significant marker compound degradation after exposure to 1.2 million lux-hours of cool white fluorescent light per ICH Q1B conditions. Avoidance of concurrent administration with oxytocin within 4 hours is recommended due to observed additive uterine contractile effects that increase perfusion expulsion velocity beyond measurable retention in 20% of animals in preliminary compatibility evaluations.

When susceptible mares demonstrate delayed uterine clearance following natural cover or artificial insemination — defined as intrauterine fluid accumulation exceeding 2 cm depth on transrectal ultrasonography at 4-8 hours post-breeding — Shanzha-derived uterine perfusion solutions are infused as a component of the standard post-breeding lavage protocol for persistent mating-induced endometritis (PMIE). The regulatory environment for equine reproductive therapeutics is defined by FEI Clean Sport regulations governing prohibited substances in competition animals, the International Federation of Horseracing Authorities (IFHA) Article 6 on therapeutic substance detection, and the European Horserace Scientific Liaison Committee (EHSLC) harmonized screening limits; all components of the Shanzha extract must be screened against the FEI Equine Prohibited Substances List prior to formulation for competition horses. The formulation addition ratio for equine uterine lavage specifies API dilution at 1:10 to 1:15 (v/v) with sterile lactated Ringer's solution or 0.9% saline, yielding final total solids of 1.3-2.8% (w/v); lactated Ringer's is preferred when repeated lavage cycles are anticipated within a 48-hour period due to the buffering capacity of sodium lactate against local pH depression. Downstream manufacturing for the equine segment employs aseptic filling of pre-sterilized 50 mL Type I borosilicate glass vials in Grade A laminar airflow stations, with terminal moist-heat sterilization at 121°C for 15 minutes and an F₀ value of ≥8; alternative terminalization by autoclaving at 115°C for 30 minutes is applied when thermal degradation of heat-labile flavonoid glycosides must be minimized, with marker compound recovery verified at ≥95% post-sterilization by HPLC. Terminal product configurations include sterile 60 mL single-use syringes pre-filled under aseptic conditions with luer-lock adapters for direct catheter attachment, and 50 mL multidose vials requiring withdrawal via sterile needle and syringe at the time of administration. Administration in the mare is performed 4-6 hours post-breeding via a sterile, flexible equine uterine catheter (85-100 cm length, 10 French diameter) passed through the cervix under per-vulvar manual guidance; infusion volumes of 30-60 mL are delivered by slow hand pressure over 3-5 minutes, with the operator monitoring for backflow through the cervical os. Experience at equine reproduction centers indicates that performance of the lavage in the standing, sedated mare using 0.01-0.02 mg/kg detomidine hydrochloride intravenously reduces patient movement that otherwise causes catheter displacement and suboptimal fluid distribution within the uterine lumen. Published data for this specific extract configuration in PMIE mares is limited; fertility outcome comparisons against traditional saline-only lavage should be generated by controlled breeding trials prior to evidence-based claims of conception rate improvement.

Sterile injectable manufacturing: aseptic fill-finish and terminal sterilization windows

The transition from concentrated liquid extract API to terminally sterilized injectable solution requires resolution of a defined process conflict: the triterpenic acid fraction of C. pinnatifida exhibits thermal degradation above 121°C when held for extended exposure, while compendial sterility for aqueous intrauterine injectables demands moist-heat terminal sterilization at 121°C for 15 minutes (F₀ ≥8) per USP <71> and EU GMP Annex 1. Resolution is achieved through formulation addition ratios that keep marker compound exposure within acceptable degradation limits: API is diluted with Water for Injection at 1:5 to 1:25 (v/v), producing total solids of 0.8-5.6% (w/v), with sodium chloride added to achieve isotonicity at 290-310 mOsm/kg verified by freezing point depression osmometry. Degradation kinetics for hyperoside under the 121°C/15-minute cycle indicate marker recovery of 92-95% relative to unsterilized controls when formulation pH is maintained at 5.5-6.5 with citrate-phosphate buffer; degradation accelerates below pH 4.5 due to acid-catalyzed glycosidic bond hydrolysis. The downstream production process for terminally sterilized injectable solutions proceeds through compounding in closed stainless steel vessels under N₂ overlay, 0.45 µm clarifier filtration, 0.22 µm bioburden reduction filtration, aseptic filling into Type I borosilicate glass containers in a Grade A / ISO 5 environment maintaining unidirectional airflow velocity of 0.36-0.54 m/s, subsequent sealing, and terminal load autoclaving. The aseptic fill-finish line is qualified per ISO 13408-1 with process simulation (media fills) demonstrating a contamination rate of NMT 0.1% at a 95% confidence interval across 3 consecutive batches; fill volumes are monitored by in-line checkweighing with automatic rejection of units deviating by ±2% from target. Endotoxin control is validated by LAL kinetic chromogenic assay per USP <85> with an acceptance limit of NMT 0.5 EU/mL in the finished injectable, and particulate matter compliance per USP <788> is verified using light obscuration with limits of NMT 6000 particles ≥10 µm and NMT 600 particles ≥25 µm per container. Terminal product configurations include 10 mL clear glass ampoules for single-dose intrauterine administration, 20 mL and 50 mL rubber-stoppered vials for multi-dose withdrawal, and 100 mL PVC-free infusion bags for gravity-drip uterine irrigation in field conditions. Batch manufacturing records from commercial lines report that foaming during high-speed compounding at agitation rates exceeding 500 rpm entrains air that increases dissolved oxygen and accelerates oxidative degradation of chlorogenic acid derivatives, necessitating vacuum degassing to dissolved oxygen levels NMT 0.5 mg/L prior to filtration. Pre-drying of the API is not required for injectable manufacturing at relative humidity ≤60%; above 60% RH, lyophilized powder intermediate is recommended to avoid moisture-induced hydrolysis of ester-linked triterpenic acid glycosides during preconditioning.

Oral granule and premix manufacturing for herd-level reproductive management involves spray-drying the liquid Shanzha extract onto a pharmaceutically acceptable carrier matrix — typically maltodextrin DE 12-18, pregelatinized starch, or microcrystalline cellulose — followed by fluid-bed granulation to achieve the particle size distribution, bulk density, and flow properties required for uniform blending into compound feed or administration as an oral drench. The industry compliance framework for this segment is anchored in EC Regulation 1831/2003 for zootechnical feed additives (category: reproductive performance enhancers), GB/T 14699.1-2017 for sampling procedures of animal feeding stuffs, and WHO/FAO good practices for the manufacture of veterinary premixes. The formulation addition ratio for feed premix intermediates specifies API incorporation at 0.5-2.0% (w/w) of dry premix mass, corresponding to a carrier-to-extract ratio of 50:1 to 200:1 after spray drying; the resulting premix is further diluted at the feed mill at 1:100 to 1:500 into finished compound feed, yielding final API-derived solids in feed of 0.001-0.02% (w/w). The downstream production process commences with spray drying in a co-current pilot-scale spray dryer (e.g., GEA Niro Mobile Minor or equivalent) at inlet temperature 150-170°C, outlet temperature 65-75°C, atomizer wheel speed 20,000-25,000 rpm, and feed solids adjusted to 15-20% (w/v) by dilution of the API concentrate. The resultant spray-dried powder, exhibiting bulk density of 0.35-0.50 g/mL and residual moisture NMT 5% (Karl Fischer), is subsequently granulated in a fluidized bed granulator (Glatt GPCG 3.1 or equivalent) at inlet air temperature 60-70°C, product temperature 35-40°C, and binder spray rate 10-15 g/min using 5% (w/v) aqueous polyvinylpyrrolidone K30 solution as the granulating liquid. Granule particle size is controlled to a target distribution of 200-800 µm with NMT 15% fines below 100 µm verified by sieve analysis per GB/T 14699.1-2017. Blend uniformity in the final feed premix is validated by assaying 10 stratified samples per batch, with the coefficient of variation of marker compound concentration held to NMT 5%; failure to meet this threshold triggers re-mixing for additional 5-10 minutes in a ribbon blender operating at 20-25 rpm. Terminal product configurations include 500 g, 1 kg, and 5 kg low-density polyethylene bags with moisture barrier liners for dairy and swine premix distribution, and 10 g and 20 g aluminum foil sachets for oral granule administration to individual breeding animals. Stability data for granulated products supports 24-month shelf life at 15-25°C and relative humidity ≤60%; at relative humidity exceeding 60%, caking of maltodextrin-based granules occurs within 30 days due to hygroscopic water uptake exceeding 8% moisture content, warranting pre-drying of the carrier matrix to ≤2% moisture before spray drying.

When field reconstitution replaces terminal sterilization in cold-chain-limited distribution

Lyophilized Shanzha extract powder for ex tempore reconstitution into uterine irrigation solution addresses distribution channels where finished liquid products cannot be maintained under continuous refrigeration and cold-chain costs exceed the economic threshold for food-animal veterinary products. The compliance landscape governing lyophilized veterinary powders includes USP <921> for water content determination (Karl Fischer coulometric method), USP <905> for uniformity of dosage units, WHO/FAO good practices for sterile veterinary powder manufacture where sterility claims are asserted, and VICH GL3 (stability testing of new veterinary drug substances and medicinal products). The formulation addition ratio for the lyophilized product specifies reconstitution of 1 g sterile lyophilized powder with 50 mL sterile Water for Injection or sterile 0.9% sodium chloride injection, yielding a working solution of 2.0% (w/v) total solids equivalent to a 1:10 dilution of the original concentrated liquid API. The downstream production process for lyophilized intermediates consists of formulation of the liquid API with bulking agents — mannitol at 2-4% (w/v) or glycine at 1-2% (w/v) — to provide cake integrity; sterile filtration through 0.22 µm PVDF membrane into sterile Type I borosilicate glass vials in Grade A / ISO 5 aseptic conditions; lyophilization in a shelf freeze dryer (e.g., SP Scientific LyoStar III or equivalent) with freezing to -45°C at 0.5°C/min, primary drying at shelf temperature -15°C and chamber pressure 100 mTorr for 24-36 hours, and secondary drying at 25°C for 6-8 hours until residual moisture reaches NMT 2% (w/w) by Karl Fischer titration. Reconstitution behavior is specified at ≤2 minutes to complete dissolution upon addition of 50 mL diluent at 20-25°C with gentle swirling; vigorous shaking is contraindicated due to foaming that generates visible bubbles for 10-15 minutes post-reconstitution and may interfere with accurate volumetric withdrawal. Terminal product configurations include 1 g, 5 g, and 10 g lyophilized cakes in Type I glass vials sealed with bromobutyl rubber stoppers and aluminum flip-cap overseals; the reconstituted solution is assigned a 6-hour in-use shelf life at 15-25°C and 24-hour shelf life at 2-8°C. The manufacturing rationale for selection of lyophilization over spray drying in this segment is the preservation of triterpenic acid glycoside integrity: spray drying at outlet temperatures exceeding 75°C produces marker compound degradation of 3-6% relative to lyophilized controls, while lyophilization maintains marker recovery at ≥97% by HPLC-DAD assay. Published data for the long-term stability of this specific lyophilized configuration under tropical storage conditions (ICH Zone IVb) is limited; accelerated stability assessment at 40°C/75% RH for 6 months is recommended by the manufacturer for each new vial configuration prior to assignment of final shelf life.

Tablet compression and capsule filling parameters for breeding-stock oral dosing

Compressed tablet and hard gelatin capsule dosage forms of Shanzha extract are manufactured for oral administration to breeding bulls, rams, and companion animals where intrauterine perfusion is not clinically indicated but reproductive support is sought through systemic delivery of the triterpenic acid and flavonoid fractions. The compliance framework for oral solid dosage forms encompasses USP <701> for disintegration testing, USP <711> for dissolution testing, USP <1216> for friability, European Pharmacopoeia 2.9.8 for resistance to crushing (tablet hardness), and VICH GL14 (quality of new veterinary drug substances and medicinal products). Formulation addition ratios for compressed tablets specify API-derived spray-dried powder incorporated at 100-500 mg per tablet, representing 30-60% (w/w) of the finished tablet mass, with excipient systems consisting of microcrystalline cellulose (25-45% w/w), croscarmellose sodium (2-4% w/w) as disintegrant, colloidal silicon dioxide (0.5-1.0% w/w) as glidant, and magnesium stearate (0.5-1.0% w/w) as lubricant. For capsule formulations, the same spray-dried powder intermediate is mixed with lactose monohydrate (30-50% w/w) and filled into hard gelatin capsules size 0 or size 1 using an automatic capsule filling machine (e.g., Bosch GKF 2600 or equivalent) at 75,000-150,000 capsules/hour with weight variation controlled to ±4% per USP <905>. The downstream production process for tablets proceeds through either direct compression of the spray-dried powder blend — viable when the extract powder exhibits Carr's compressibility index ≤25 and Hausner ratio ≤1.25 — or wet granulation when the extract fraction exceeds 50% (w/w); wet granulation employs a high-shear granulator (Diosna P 1/6 or equivalent) with water as granulating liquid at 8-12% (w/w) of dry blend mass, followed by tray drying at 50-60°C to final moisture NMT 3%, and dry milling through a 0.8 mm sieve. Compression is carried out on a rotary tablet press (Korsch XL 400 or equivalent) at compression force 8-20 kN, maintaining tablet hardness of 30-60 N, disintegration time NMT 15 minutes in water at 37°C, and friability NMT 1.0% after 100 drum revolutions. Production-scale observations indicate that extract batches with residual moisture exceeding 3% cause sticking to punch faces and weight variation drift of ±3% over 30-minute compression runs, necessitating re-drying and re-blending before compression is resumed. Terminal product configurations include 1000-tablet HDPE bottles with induction-sealed closures, 10-tablet and 30-tablet PVC/PVDC blister packs, and 100-capsule or 500-capsule HDPE bottles with desiccant canisters. Dissolution testing per USP <711> is performed with Apparatus 2 (paddle) at 50 rpm in 900 mL of 0.1 M hydrochloric acid at 37°C, with the acceptance criterion of Q = 75% release of total triterpenic acid markers within 45 minutes. Long-term stability of compressed tablets stored in HDPE bottles at 25°C/60% RH is assigned at 36 months, with photostability confirmed per ICH Q1B at 1.2 million lux-hours exposure showing no marker loss exceeding 2% in amber glass or opaque HDPE containment.